Purpose

Careful patient selection plays a crucial role in avoiding overtreatment and further increases survival rates in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer (CRC) with peritoneal metastases (PM).

Methods

The clinical and molecular factors influencing survival in patients who had undergone CRS with HIPEC between January 2015 and December 2018 were analyzed.

Results

Sixty-six patients underwent CRS with HIPEC during the study period. The median overall survival (OS) was 36 months, with a 3-year OS of 43%. Multivariate analysis revealed increased PCI (HR: 1.21; 95% CI: 1.02–1.41; p = 0.020), right-sided primary tumor (HR: 3.01; 95% CI: 1.27–7.13; p = 0.017), and BRAF V600E mutation (HR: 4.55; 95% CI: 1.21–17.21; p = 0.025) as independent predictors for worse OS.

Conclusion

In addition to confirming the prognostic role of PCI, our study extends the role of BRAF mutation and right primary tumor location as markers for worse prognosis.

中文翻译：

---

接受细胞减灭术和腹腔热灌注化疗治疗结直肠癌腹膜癌患者的临床和分子特征

 目的

仔细的患者选择对于避免过度治疗至关重要，并进一步提高接受细胞减灭术 (CRS) 和腹膜热腹腔化疗 (HIPEC) 治疗伴有腹膜转移 (PM) 的结直肠癌 (CRC) 患者的生存率。

 方法

分析2015年1月至2018年12月期间接受CRS联合HIPEC的患者生存的临床和分子因素。

 结果

在研究期间，66 名患者接受了 HIPEC 的 CRS 治疗。中位总生存期 (OS) 为 36 个月，3 年 OS 为 43%。多变量分析显示 PCI 增加（HR：1.21；95% CI：1.02–1.41；p = 0.020）、右侧原发肿瘤（HR：3.01；95% CI：1.27–7.13；p = 0.017）和BRAF V600E 突变（HR：4.55；95% CI：1.21–17.21；p = 0.025）作为较差 OS 的独立预测因子。

 结论

除了证实 PCI 的预后作用外，我们的研究还扩展了 BRAF 突变和右侧原发肿瘤位置作为预后较差标记的作用。